Bristol-Myers Squibb announces the latest progress in protein degradation therapy and cancer immunotherapy

A few days ago, executives of Bristol-Myers Squibb (BMS) introduced the company's R&D strategy and key projects at investor events

▲Bristol-Myers Squibb's drug discovery platform (picture source: Bristol-Myers Squibb's official website)

The protein homeostasis technology platform generates a variety of innovative therapies

Bristol-Myers Squibb's Protein Homeostasis technology platform uses a variety of different methods to achieve the effect of degrading target proteins, including molecular glue compounds called CELMoD

▲Bristol-Myers Squibb's protein homeostasis technology platform has generated a variety of innovative therapies under research (picture source: Bristol-Myers Squibb official website)

Among them, a number of CELMoDs based on the further optimization of dosamine molecules have entered the clinical development stage

▲The mechanism of CELMoD degrading Ikaros/Aiolos protein (picture source: Bristol-Myers Squibb official website)

Iberdomide, developed based on this platform, combined with other standard treatment drugs for multiple myeloma, has shown good anti-cancer activity in clinical trials for multiple myeloma patients who have received a variety of pre-treatments

▲Preliminary clinical trial results of Iberdomide triple combination therapy (picture source: Bristol-Myers Squibb official website)

Another CELMoD therapy CC-92480 showed more differentiated clinical activity in the phase 1 clinical trial.

▲ Results of Phase 1 clinical trial of CC-92480 (Image source: Bristol-Myers Squibb official website)

Bristol-Myers Squibb’s goal is to replace lenalidomide and pomalidomide with these two drugs in the future

In addition, the company’s optimized CELMoD therapy CC-99282 for non-Hodgkin’s lymphoma also showed good anti-cancer activity in early clinical trials.

Multi-directional modified cancer immunotherapy

Bristol-Myers Squibb's anti-PD-1 antibody Opdivo has been approved by the FDA to treat a variety of cancer types

In terms of expanding the scope of application of Opdivo, it is used in combination with chemotherapy as an adjuvant therapy.

▲Clinical trial results of Opdivo combined with chemotherapy for adjuvant treatment of early-stage lung cancer patients (picture source: Bristol-Myers Squibb official website)

In addition, the combination of Opdivo and LAG-3 antibody relatlimab significantly improved the progression-free survival of patients in a phase 3 clinical trial of first-line treatment of melanoma patients

Image source: Bristol-Myers Squibb official website

In the development of a new generation of cancer immunotherapy, Bristol-Myers Squibb's CC-95251 is a monoclonal antibody targeting SIRPα

▲ Mechanism of action of CC-95251 (picture source: Bristol-Myers Squibb official website)

It has shown positive activity and safety in clinical trials for the treatment of non-Hodgkin's lymphoma, reaching an objective response rate of 41%

BMS-986415 is an IL-12 fusion protein therapy jointly developed with Dragonfly Therapeutics

▲Introduction of BMS-986415 (picture source: Bristol-Myers Squibb official website)

Aiming at the inhibitory effect of the tumor microenvironment on immune cells, another R&D direction of the company is to target the IL-8 signaling pathway

▲The immunosuppressive effect of IL-8 (picture source: Bristol-Myers Squibb official website)

BMS-986253 is an innovative anti-IL-8 antibody therapy, which is used in combination with the anti-PD-1 antibody Opdivo to treat melanoma patients who have been treated with PD-1 inhibitors and CTLA-4 inhibitors.

In addition, Bristol-Myers Squibb is also developing anti-cancer therapies other than cancer immunotherapy

Further expand the cell therapy technology platform

The company’s CD19-targeted CAR-T cell therapy Breyanzi, as a second-line therapy, has significantly improved the event-free survival, complete remission rate, and complete remission rate of patients in a phase 3 clinical trial for the treatment of patients with large B-cell lymphoma compared with standard treatments.
Progression-free survival
.

Bristol-Myers Squibb is also collaborating with a number of external companies and research institutions to develop next-generation cell therapies, including CAR-T therapy targeting dual antigens, TCR-T cell therapy for solid tumors, and allogeneic CAR-T therapy Wait a minute
.

Executives from Bristol-Myers Squibb also introduced its potential "first-in-class" TYK2 allosteric inhibitor deucravacitinib, the innovative anticoagulant drug milvexian jointly developed with Janssen, and potential "first-in" -class" cardiovascular drug mavacamten and other innovative therapies research and development layout
.
Due to space limitations, this article will not introduce them one by one
.
Reply "BMS" to WuXi AppTec WeChat account to download the investor activity PPT report
.

Reference materials:

[1] Bristol Myers Squibb Investor Event.
Retrieved November 19, 2021, from https://s21.
q4cdn.
com/104148044/files/doc_presentations/2021/2021-BMS-Investor-Event-Presentation.
pdf

(The original text has been deleted)